Search
forLearn
5 / 801 resultslearn multipeptides
learn apple polyphenol
learn oligopeptide-71
learn microbiota modulator
Research
5 / 384 resultsresearch Mite Burden and Immunophenotypic Response to Demodex musculi in Swiss Webster, BALB/c, C57BL/6, and NSG Mice
NSG mice had the most mites, and genetic factors affect immune response and susceptibility.
research Alopecia in Rhesus macaques correlates with immunophenotypic alterations in dermal inflammatory infiltrates consistent with hypersensitivity etiology
Hair loss in Rhesus macaques may be caused by a skin allergy-related condition.
research Clinical, histological and immunophenotypic findings in a mare with a mammary lymphoma associated with anaemia and pruritus
A mare had severe symptoms and died from a large lymphoma.
research Basal cell carcinoma possibly originates from the outer root sheath and/or the bulge region of the vellus hair follicle
Basal cell carcinoma may start from parts of tiny hair follicles.
research Trichilemmoma.Features of keratin expression in CS-5 trichocyst system tumors.
Immunohistochemistry helps accurately identify and differentiate malignant trichilemmoma.
Community Join
5 / 1000+ resultscommunity Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
community Pelage are still talking about phase 2a results of PP405
community Pp405 phase 2a clinical results
PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.
community IGE Hair Loss and Miniaturization
A 23-year-old male is experiencing diffuse hair loss and miniaturization, possibly due to high IGE levels after using tofacitinib. He seeks advice and has not yet consulted a dermatologist.
community Trial for TDM-105795 update from research office
The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.